The untapped power of multivariate analysis for target identification in cancer drug discovery
Discover how multivariate analysis is transforming target identification in cancer drug discovery by moving beyond traditional methods.
Cancer
- Latest Posts
In Depth 10 Jun 2024
ASCO 2024: The latest advances in oncology clinical trials
Biotechs from all over the country as well as other parts of the world showcased recent pipeline advancements in oncology clinical trials at ASCO 2024.
Best in Biotech 6 Jun 2024
Eight biotech companies advancing the field of siRNA
Explore the growing sector of siRNA and discover eight biotech companies spearheading this innovative field.
In Depth 5 Jun 2024
Evolving standards of care: new treatments for cervical cancer
New treatments for cervical cancer aim to broaden therapeutic options, and improve current standards of care for patients.
In Depth 30 May 2024
Covalent biologics: a new class of drugs on the horizon
The field of covalent biologics has made headway recently, as the only biotech in the space has bagged $100 million to move its pipeline to the clinic.
Best in Biotech 30 May 2024
Stem cell therapy’s avant-garde: Eight companies leading the way
Stem cell therapy has gained traction over the recent years and the market is growing, discover eight companies advancing the field.
ADVERTISEMENT
ADVERTISEMENT
In Depth 22 May 2024
The undruggable cancer target: KRAS inhibitors move ahead in the clinic
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio’s spinout.
Best in Biotech 21 May 2024
Eight companies spearheading Philadelphia’s biotech industry
Often called the Cellicon Valley due to its focus on cell and gene therapy, discover eight Philadelphia biotech companies to know about.
Cell avidity-tuning ensures safe CAR-T therapy for solid tumors
Learn more about the potential of cell avidity in designing potent and safe CAR-T treatments for solid tumors.
In Depth 9 May 2024
BTK inhibitors: can these drugs tackle cancer and autoimmunity?
BTK inhibitors were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases.
Best in Biotech 2 May 2024
Eight monoclonal antibody biotechs making strides in the clinic
In this article, we take a look at eight biotechs advancing their monoclonal antibodies through the clinic that have made the news in recent times.
In Depth 24 Apr 2024
Overcoming toxicities: are IL-2 smart cytokines the next big thing?
A more advanced form of IL-2 cytokine therapy called IL-2 smart cytokines could overcome side effects, and shake up cancer care as we know it.
ADVERTISEMENT
